It was therefore concluded that loss of function mutations of SUR1, a regulatory subunit of KATP channels, is associated with PAH and that channel function can be rescued via pharmacologic activation; thus, SUR1 and KATP channels may represent a therapeutic target in PAH [12]. Here, ABCC8 is linked to pulmonary arterial hypertension.